title: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
abstract: OBJECTIVE
  Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed a trial to investigate this matter.
  
  
  METHODS
  We developed and conducted a placebo-controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods.
  
  
  RESULTS
  The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed a similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P < or = .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively).
  
  
  CONCLUSIONS
  Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.
authors.affiliation: Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Barton
authors.forename: C L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: S K
authors.initials: SK
authors.lastname: Quella
authors.forename: J A
authors.initials: JA
authors.lastname: Sloan
authors.forename: M H
authors.initials: MH
authors.lastname: Veeder
authors.forename: J R
authors.initials: JR
authors.lastname: Egner
authors.forename: P
authors.initials: P
authors.lastname: Fidler
authors.forename: P J
authors.initials: PJ
authors.lastname: Stella
authors.forename: D K
authors.initials: DK
authors.lastname: Swan
authors.forename: N L
authors.initials: NL
authors.lastname: Vaught
authors.forename: P
authors.initials: P
authors.lastname: Novotny
mesh_terms: D000293:Adolescent; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen; D014810:Vitamin E